Coloplast CEO: "It's important for me we don't turn into a company, where it only works if we invented it"

Coloplast displayed a surprising will to buy, when the company Tuesday presented its long-term strategy. The headlines were to reinforce the company's product pipeline and to smash the US and Chinese competition.

Photo: Coloplast / PR

A lot of new information was laid on the table on Tuesday, when Coloplast presented its long-term strategy until 2025, but one of the elements that immediately drew headlines was Coloplast's plan to make more acquisitions.

In the future, the company is actively placing stakes on acquiring promising products and technologies from other companies, which a surprising move for Coloplast, which is not the kind of company, where you would typically expect this strategy.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs